Table 2.

Genetic aberrations and immunohistochemical results

CharacteristicsTotal cases (%)DLBCL + MALT (%)DLBCL (%)P*
Genetic aberration
    BCL6 translocation (n = 82)
        Positive16 (20)11 (28)5 (12)0.053
        Negative66 (80)28 (72)38 (88)
    c-MYC translocation (n = 73)
        Positive7 (10)3 (9)4 (10)NS
        Negative66 (90)31 (91)35 (90)
    FOXP1 translocation (n = 97)
        Positive4 (4)3 (7)1 (2)NS
        Negative93 (96)42 (93)51 (98)
    MALT1 translocation (n = 105)
        Positive0 (0)0 (0)0 (0)NS
        Negative105 (100)51 (100)54 (100)
    IGH translocation (n = 112)
        Positive36 (32)14 (27)22 (36)NS
        Negative76 (68)37 (73)39 (64)
    Extra copies of MALT1/BCL2 (n = 106)
        Positive25 (24)9 (18)16 (29)0.123
        Negative81 (76)42 (82)39 (71)
    Extra copies of FOXP1/BCL6 (n = 101)
        Positive21 (21)3 (7)18 (32)0.001
        Negative80 (79)42 (93)38 (68)
    Extra copies of c-MYC (n = 73)
        Positive7 (10)1 (3)6 (15)0.078
        Negative66 (90)33 (97)33 (85)
Immunohistochemistry
    CD10 expression (n = 141)
        Positive56 (40)20 (34)36 (43)NS
        Negative85 (60)38 (66)47 (57)
    BCL6 expression (n = 141)
        Positive74 (52)34 (59)40 (48)NS
        Negative67 (48)24 (41)43 (52)
    MUM1 expression (n = 141)
        Positive82 (58)34 (59)48 (58)NS
        Negative59 (42)24 (41)35 (42)
    Subgroup by Hans (n = 141)
        GCB72 (51)29 (50)43 (52)NS
        Non-GCB69 (49)29 (50)40 (48)
    FOXP1 expression (n = 82)
        Positive31 (38)16 (53)15 (29)0.025
        Negative51 (62)14 (47)37 (71)
  • * Fisher's exact probability test.

  • In one case, t(11;18)/API2-MALT1 was positive in MALT lymphoma cells.